Abstract
Full text: A commercial system-MotionSim XY/4D(TM) capable of simulating two-dimensional tumour motion and measuring planar dose with diode-matrix was evaluated at the Alfred Hospital, for establishing patient-specific QA programme of respiratory gated treatment of lung cancer. This study presents the investigation of accuracies, limitations and the practical aspects of that system. Planar doses generated on iPlan-TM by mapping clinical beams to a scanned-in water phantom were measured by MotionSim XY/4D-TM with 5 cm water equivalent build-up at normal incidence. The gated delivery using ExacTrac-TM through tracking infrared markers simulating external respiration surrogate was measured simultaneously with Gaf-ChromicR RTQA2 film and MapCHECK{sub 2TM}. Dose maps of both non-gated and gated beams with 30% duty cycle were compared with both film and diodes measurements. Differences in dose distribution were analysed with built-in tools in MapCHECK2 TM and the effect of residual motion within the beamenabled window was then assessed. Preliminary results indicate that difference between Gafchromic film and MapCHECK2 measurements of same beam was ignorable. Gated dose delivery to a target at 9 mm maximum motion was in good agreement with planned dose. Complement to measurements suggested in AAPM Report No.9 I I, this QA device can detect any random error and
More>>
Wen, C;
Ackerly, T;
Lancaster, C;
Bailey, N
[1]
- WBRC, The Alfred Hospital, Melbourne, Victoria, Australia (Australia)
Citation Formats
Wen, C, Ackerly, T, Lancaster, C, and Bailey, N.
Evaluation of MotionSim XY/4D for patient specific QA of respiratory gated treatment for lung cancer.
Australia: N. p.,
2011.
Web.
Wen, C, Ackerly, T, Lancaster, C, & Bailey, N.
Evaluation of MotionSim XY/4D for patient specific QA of respiratory gated treatment for lung cancer.
Australia.
Wen, C, Ackerly, T, Lancaster, C, and Bailey, N.
2011.
"Evaluation of MotionSim XY/4D for patient specific QA of respiratory gated treatment for lung cancer."
Australia.
@misc{etde_22066973,
title = {Evaluation of MotionSim XY/4D for patient specific QA of respiratory gated treatment for lung cancer}
author = {Wen, C, Ackerly, T, Lancaster, C, and Bailey, N}
abstractNote = {Full text: A commercial system-MotionSim XY/4D(TM) capable of simulating two-dimensional tumour motion and measuring planar dose with diode-matrix was evaluated at the Alfred Hospital, for establishing patient-specific QA programme of respiratory gated treatment of lung cancer. This study presents the investigation of accuracies, limitations and the practical aspects of that system. Planar doses generated on iPlan-TM by mapping clinical beams to a scanned-in water phantom were measured by MotionSim XY/4D-TM with 5 cm water equivalent build-up at normal incidence. The gated delivery using ExacTrac-TM through tracking infrared markers simulating external respiration surrogate was measured simultaneously with Gaf-ChromicR RTQA2 film and MapCHECK{sub 2TM}. Dose maps of both non-gated and gated beams with 30% duty cycle were compared with both film and diodes measurements. Differences in dose distribution were analysed with built-in tools in MapCHECK2 TM and the effect of residual motion within the beamenabled window was then assessed. Preliminary results indicate that difference between Gafchromic film and MapCHECK2 measurements of same beam was ignorable. Gated dose delivery to a target at 9 mm maximum motion was in good agreement with planned dose. Complement to measurements suggested in AAPM Report No.9 I I, this QA device can detect any random error and assess the magnitude of residual target motion through analysing differences between planned and delivered doses as gamma function. Although some user-friendliness aspects could be improved, it meets its specification and can be used for routine clinical QA purposes provided calibrations were performed and procedures were followed.}
place = {Australia}
year = {2011}
month = {Jul}
}
title = {Evaluation of MotionSim XY/4D for patient specific QA of respiratory gated treatment for lung cancer}
author = {Wen, C, Ackerly, T, Lancaster, C, and Bailey, N}
abstractNote = {Full text: A commercial system-MotionSim XY/4D(TM) capable of simulating two-dimensional tumour motion and measuring planar dose with diode-matrix was evaluated at the Alfred Hospital, for establishing patient-specific QA programme of respiratory gated treatment of lung cancer. This study presents the investigation of accuracies, limitations and the practical aspects of that system. Planar doses generated on iPlan-TM by mapping clinical beams to a scanned-in water phantom were measured by MotionSim XY/4D-TM with 5 cm water equivalent build-up at normal incidence. The gated delivery using ExacTrac-TM through tracking infrared markers simulating external respiration surrogate was measured simultaneously with Gaf-ChromicR RTQA2 film and MapCHECK{sub 2TM}. Dose maps of both non-gated and gated beams with 30% duty cycle were compared with both film and diodes measurements. Differences in dose distribution were analysed with built-in tools in MapCHECK2 TM and the effect of residual motion within the beamenabled window was then assessed. Preliminary results indicate that difference between Gafchromic film and MapCHECK2 measurements of same beam was ignorable. Gated dose delivery to a target at 9 mm maximum motion was in good agreement with planned dose. Complement to measurements suggested in AAPM Report No.9 I I, this QA device can detect any random error and assess the magnitude of residual target motion through analysing differences between planned and delivered doses as gamma function. Although some user-friendliness aspects could be improved, it meets its specification and can be used for routine clinical QA purposes provided calibrations were performed and procedures were followed.}
place = {Australia}
year = {2011}
month = {Jul}
}